Quick Answer
Amneal Pharmaceuticals, Inc. reported Research And Development Expense of $186.18 million for the year ending 2025.
- Amneal Pharmaceuticals, Inc. showed a decrease of -2.4% in Research And Development Expense from 2024 to 2025.
- This data is from Amneal Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: $47.18 million | Q3 2017: $41.32 million | Q1 2018: $44.21 million | Q2 2018: $50.34 million | Q3 2018: $42.35 million | Q1 2019: $53.86 million | Q2 2019: $48.02 million | Q3 2019: $38.13 million | Q1 2020: $36.38 million | Q2 2020: $45.57 million | Q3 2020: $44.52 million | Q1 2021: $48.18 million | Q2 2021: $52.86 million | Q3 2021: $48.93 million | Q1 2022: $52.80 million | Q2 2022: $50.75 million | Q3 2022: $50.24 million | Q1 2023: $38.69 million | Q2 2023: $37.80 million | Q3 2023: $41.38 million | Q1 2024: $39.30 million | Q2 2024: $36.05 million | Q3 2024: $61.10 million | Q1 2025: $40.04 million | Q2 2025: $47.96 million | Q3 2025: $63.35 million.
- Over the full 10 years of available data (2016 to 2025), Amneal Pharmaceuticals, Inc.'s Research And Development Expense has grown by 4.0%.
- Historical annual values: Fiscal year 2025: $186.18 million | Fiscal year 2024: $190.71 million | Fiscal year 2023: $163.95 million | Fiscal year 2022: $195.69 million | Fiscal year 2021: $201.85 million | Fiscal year 2020: $179.93 million | Fiscal year 2019: $188.05 million | Fiscal year 2018: $194.19 million | Fiscal year 2017: $171.42 million | Fiscal year 2016: $179.02 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: